As an important European Life Sciences stock exchange, Switzerland offers an outstanding framework for procuring capital. The SIX Swiss Exchange invests 40% of its traded capital in Life Sciences projects. The economic and scientific environment boasts the presence of successful international chemical and pharmaceutical companies, such as Novartis and Roche, as well as innovative firms from the medical technology, biotechnology, and nanotechnology sectors, making it highly suitable for strategic partnerships, licensing, or patent sales. Modern infrastructure, high quality of life, and access to excellently trained employees supplement the extremely positive conditions for a strong and future-oriented biotechnology industry in Switzerland.
Switzerland is one of the best and most innovative locations for biotechnology in Europe. Local companies hold leading positions throughout many sectors and thus attract capital and researchers from all over the world.